Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management.
Jorge J CastilloBrady Ernesto Beltrán-GárateLuis E Malpica-CastilloMario L Marques-PiubelliRoberto N MirandaPublished in: Leukemia & lymphoma (2021)
Anaplastic lymphoma kinase-positive (ALK+) large B-cell lymphoma (LBCL) is a rare CD20-negative aggressive lymphoma. Given its rarity, data on ALK + LBCL are scarce and limited to case reports and small case series. Our systematic review included 184 unique cases published in the literature and shows that ALK + LBCL can affect individuals at any age, has a male predominance and is not associated with chronic viral infections. The malignant cells express ALK, VS38c, BLIMP-1, EMA, c-MYC, and BOB-1. The STAT3/STAT5, PI3K/AKT, PLCG2, and ERK pathways are important in the pathophysiology of ALK + LBCL. The prognosis of ALK + LBCL is poor with a 5-year survival rate of 28%. Early disease stage is associated with better outcomes. ALK inhibitors and other targeted agents could be of value in the treatment of ALK + LBCL. Additional research is needed to better understand, diagnose and treat ALK + LBCL.
Keyphrases
- advanced non small cell lung cancer
- systematic review
- diffuse large b cell lymphoma
- pi k akt
- cell proliferation
- signaling pathway
- sars cov
- randomized controlled trial
- epidermal growth factor receptor
- type diabetes
- adipose tissue
- metabolic syndrome
- meta analyses
- deep learning
- cell death
- protein kinase
- replacement therapy
- free survival
- data analysis